The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 69.00
Bid: 68.00
Ask: 70.00
Change: 0.00 (0.00%)
Spread: 2.00 (2.941%)
Open: 69.00
High: 69.00
Low: 69.00
Prev. Close: 69.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ProAxsis Wins Innovative Business of Year in NI

4 Jun 2018 07:00

RNS Number : 1104Q
NetScientific PLC
04 June 2018
 

 

 

NetScientific plc

("NetScientific" or the "Company" or the "Group")

 

ProAxsis Winner of Innovative Business of the Year Award in Northern Ireland

 

 

London, UK - June 4th, 2018 - NetScientific plc ("NetScientific", AIM: NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company ProAxsis has been granted the Innovative Business of the Year award at the Business Eye First Trust Awards (BEFTAs), an for small businesses in Northern Ireland. The award, issues by First Trust Bank, saw ProAxsis emerge the elected winner amongst a group of companies from diverse sectors.

 

Commenting on the news, NetScientific's Chief Executive Officer and Chairman of ProAxsis, Francois R. Martelet said: "We are extremely pleased with this outcome and want to extend our congratulations to the ProAxsis team for the ongoing hard work and dedication. It is splendid to see their efforts materialising and gaining recognition, and we look forward to their continued progress for what has been a fantastic year for them thus far."

 

NetScientific holds 54% of ProAxsis on a fully-diluted basis.

 

The full text of the announcement from ProAxsis can be found below.

 

# # #

 

For more information, please contact:

 

  NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

Tel: +44 (0)20 3514 1800

 

Consilium Strategic Communications

Mary-Jane Elliott Jessica Hodgson /

Chris Welsh / Laura Thornton

 

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior / David Arch / Ben Maddison

 Tel: +44 (0) 20 7710 7600

 

 

ProAxsis wins Innovative Business of the Year Award

Date: June 4th 2018

ProAxsis Limited has been declared as the "Innovative Business of the Year" at the Business Eye First Trust Awards (BEFTAs) for small businesses in Northern Ireland.

The glittering awards ceremony took place on the evening of Thursday May 31st at the Crowne Plaza Hotel in Belfast, and was compered by the UTV newsreader and Northern Ireland correspondent for ITV, Marc Mallett. Over 400 people were in attendance, with more than 50 Northern Irish businesses shortlisted across the 14 award categories.

The ProAxsis team were announced as the Innovative Business of the Year by Tina McKenzie, the Chair of the Federation of Small Businesses NI, who sponsored the innovation category.

Dr David Ribeiro, CEO of ProAxsis, commented: "This is fabulous recognition for the whole team at ProAxsis, who work incredibly hard in order to maximise the potential of our novel ProteaseTag® technology. We're thrilled to have won our first BEFTA, in what was described as one of the most competitive categories of the event, and would like to thank the organisers, Business Eye, as well as the judging panel and the sponsors for the event."

ProAxsis is part of the NetScientific group and is one of the group's core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

About ProAxsis Limited:

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease. Its first commercialised immunoassay measures neutrophil elastase, a leading indicator of infection and inflammation in patients with Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis, and an important drug target. The rapid and easy-to-use tests being developed by ProAxsis incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProteaseTags® provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.

ProAxsis is part of the NetScientific Group and is one of the Group's core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRALIFIIRSIFIIT
Date   Source Headline
27th May 20214:36 pmRNSPrice Monitoring Extension
24th May 20217:00 amRNSProAxsis Update
21st May 202111:00 amRNSPrice Monitoring Extension
20th May 20214:19 pmRNSPDS Announces Release of PDS0101 Abstract
20th May 20217:00 amRNSEMV Capital Advises on £3.4m PointGrab Fundraise
18th May 20217:00 amRNSPDS receives $4.5m from net sale of tax benefits
13th May 20213:15 pmRNSPDS Reports Results for Q1 2021 & Business Update
13th May 20217:00 amRNSEMV Capital Advises on £2.9m SageTech Fundraise
30th Apr 20217:00 amRNSPDS Announces Presentation at ASCO Annual Meeting
28th Apr 202110:08 amRNSEMV Capital Advises on £740k Fundraise for Sofant
14th Apr 20212:25 pmRNSNotice of AGM and Annual Report & Accounts
31st Mar 20219:02 amRNSPreliminary Results for the year ended 31 Dec 2020
30th Mar 20217:00 amRNSNotice of Results & Investor Presentation
18th Mar 202111:48 amRNSPDS Reports Results for FY2020 & Business Update
11th Mar 20213:26 pmRNS$60m Commitment for PDS Vaccine Consortium
23rd Feb 20217:00 amRNSPDS Biotech Consortium Update
22nd Feb 20217:00 amRNSProAxsis Update
10th Feb 202111:01 amRNSPrice Monitoring Extension
10th Feb 20219:05 amRNSSecond Price Monitoring Extn
10th Feb 20219:00 amRNSPrice Monitoring Extension
5th Feb 20214:40 pmRNSSecond Price Monitoring Extn
5th Feb 20214:35 pmRNSPrice Monitoring Extension
5th Feb 20212:06 pmRNSSecond Price Monitoring Extn
5th Feb 20212:01 pmRNSPrice Monitoring Extension
5th Feb 202111:05 amRNSSecond Price Monitoring Extn
5th Feb 202111:00 amRNSPrice Monitoring Extension
3rd Feb 20212:45 pmRNSRestoration - Netscientific plc
3rd Feb 20212:45 pmRNSPDS Phase II Trial Update & Restoration of Trading
2nd Feb 20217:30 amRNSSuspension - Netscientific plc
2nd Feb 20217:00 amRNSSuspension of Trading on AIM
25th Jan 20217:00 amRNSIssue of Shares, Director/PDMR Shareholding & TVR
4th Jan 202110:31 amRNSHolding(s) in Company
21st Dec 20202:59 pmRNSPDS Announces Publication of Data by Mount Sinai
10th Dec 20207:00 amRNSProAxsis awarded Innovate UK grant
7th Dec 202011:05 amRNSSecond Price Monitoring Extn
7th Dec 202011:00 amRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSBoard changes and Grant of Options
30th Nov 20201:56 pmRNSEMV Capital leads a £1.28m investment in SageTech
19th Nov 20207:00 amRNSProAxsis appoints DiaPharma as distributor
11th Nov 20202:10 pmRNSPDS updates on Versamune based COVID-19 vaccine
10th Nov 202012:47 pmRNSPDS Biotech Initiates VERSATILE-002 Phase 2 Trial
27th Oct 20209:46 amRNSPDS Announces Initiation of PDS0101 Phase 2 Trial
16th Oct 20207:00 amRNSNetScientific acquires 100% of portfolio company
30th Sep 20209:08 amRNSDirector/PDMR Shareholding
30th Sep 20209:07 amRNSHolding(s) in Company
30th Sep 20208:58 amRNSHolding(s) in Company
25th Sep 202012:37 pmRNSGrant of Options to Director
24th Sep 20207:00 amRNSInterim Results
2nd Sep 20207:00 amRNSHolding(s) in Company
2nd Sep 20207:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.